Retinal diseases are a growing global health concern. As populations age and diabetes becomes more prevalent, the number of people affected by macular degeneration, diabetic retinopathy, and related conditions continues to rise. Yet access to treatment remains uneven. In high-income countries, patients can typically receive intravitreal injections at specialized clinics with trained retina specialists. In many low- and middle-income countries, such care is scarce, expensive, or unavailable, leaving patients to face progressive vision loss without treatment options.

Closing this gap is a complex challenge. It requires trained ophthalmologists, adequate facilities, reliable drug supply chains, and affordable pricing. Some countries have expanded access by training general ophthalmologists to perform injections, rather than restricting the procedure to retina subspecialists. Others have adopted cost-reduction strategies, including the use of compounded alternatives and the introduction of biosimilars. Public health programs and nonprofit initiatives have also played a role. These efforts are gradually expanding the reach of retinal care and, with it, the Intravitreal Injection Market.

The stakes are high. Vision loss has profound effects on quality of life, independence, and economic productivity. For individuals, the ability to read, drive, and recognize faces may depend on timely treatment. For health systems, preventing blindness is generally less costly than supporting people who have lost vision. Expanding access to intravitreal therapy is therefore not only a matter of equity but also of sound health economics. Progress will depend on continued innovation in drug delivery, pricing, and care delivery models that reach beyond major urban centers.

People Also Ask

Can intravitreal injections be given by general ophthalmologists?
In some settings, yes. Training general ophthalmologists to perform injections has helped expand access where retina specialists are scarce, though specialist oversight is often preferred.

Are biosimilar anti-VEGF drugs available?
Yes. Biosimilars for several anti-VEGF agents have been approved in various regions, offering lower-cost alternatives that may improve access to treatment.

Tags: #GlobalOphthalmology #HealthcareAccess #DiabeticRetinopathy #Biosimilars #VisionLoss #HealthEquity